Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate
genedrive plc (AIM: GDR) Comment re: Share Price Movement
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company’s share price on 13 August 2025 which it believes was connected to postings
OptiBiotix Health plc (AIM: OPTI) Launch of SlimBiome® in leading US brand
OptiBiotix Health plc (AIM: OPTI), a life sciences company focused on products that reduce hunger and food cravings, improve the gut microbiome, and offer sweet fibres as healthy sugar alternatives,
genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds
Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
Breakthrough Pill Set to Revolutionise NHS Weight Loss Treatment
Orforglipron Weight Loss Pill Shows Promise in Landmark Trial, Paving Way for NHS Obesity Care Breakthrough
Abingdon Health plc (AIM: ABDX) Trading update
Revenue for FY25 in line with market expectations of £8.6m Continued strong revenue growth anticipated in FY26
Shortwave Life Sciences (AQSE: PSY) £250K Raised, Biotech Meets Digital Assets
StockBox spoke to Shortwave Life Sciences co-founder Stephen Murphy and executive chairman Rolf Gerritsen following the company’s £250,000 fundraise. They discussed the company’s strategic expansion into digital asset management, upcoming
Abingdon Health plc (AIM: ABDX) c. US$2.5m companion diagnostic test contract win
c. US$2.5m companion diagnostic test contract win Full CDMO service contract for development, scale-up, technical transfer, manufacture and full regulatory support
hVIVO plc (AIM: HVO) Proposed appointment of Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation and the world leader in human challenge clinical trials, announces the appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of
Avacta Therapeutics (AIM: AVCT) Announces Agreement to Sell Coris Bioconcept SRL
Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of Coris Bioconcept SRL (“Coris”) to 3B BlackBio Dx Ltd for an upfront cash consideration of £2.15 Million
Genflow Biosciences Advances Toward Human Trials for Ageing Therapies
Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.
hVIVO plc (AIM:HVO) trading update for the six months ended 30 June 2025 (H1 2025).
H1 Trading update